Program
treprostinil
Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.
Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeuticsits history only | 625 open or running | phase 4since Apr 14, 2003 | Oct 18, 1999 | Nov 2027phase 3 · NCT05943535 |
| Liquidia Technologiesits history only | 64 open or running | phase 4since Aug 7, 2026 | Jan 3, 2018 | Feb 2027phase 2 · NCT07748000 |
| Mannkindits history only | 10 open or running | phase 1since Mar 1, 2018 | Mar 1, 2018 | none ahead |
| Pharmosa Biopharm | 10 open or running | phase 1since Jul 23, 2019 | Jul 23, 2019 | none ahead |
| SciPharm SàRLits history only | 10 open or running | phase 3since Aug 12, 2011 | Aug 12, 2011 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmosa Biopharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121
- Jul 23, 2019First study: phase 1 study in Pulmonary Arterial HypertensionFirst studyNCT04041648 · 52 enrolled · United States
TargetBeta
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selexipagrule | Johnson & Johnson | phase 4 | 23 |
Studies
The one study Pharmosa Biopharm leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04041648Pulmonary Arterial Hypertension · United States | 1 | Completed | Sep 20, 2019 | 52 |
How it is read
Names in the registry
- “Inhaled Treprostinil”, 7 entries
- “treprostinil diethanolamine”, 6 entries
- “Oral Treprostinil”, 5 entries
- “treprostinil sodium”, 5 entries
- “UT-15C SR”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 38 studies
- Hypertension, Pulmonary, 17 studies
- Scleroderma, Systemic, 4 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Chronic Limb-Threatening Ischemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.